

OMPs with MA

16%


11%


11%

→ % OMPS WITH MA WITHOUT NC

16%

14%





Note 1: Due to the fact that the information is not publicly available, this Report does not include those medicines used under the 'special situations' set out in Royal Decree 1015/2009, about compassionate use, use in conditions other than those authorised, or access to foreign medicines (available here: https://www.boe.es/eli/es/rd/2009/06/19/1015). Nota 2: Data in the graph referring to advance therapies with marketing authorisation, national code and reimbursed by NHS, are not cumulative.

NC

2021

0

NHS

2022

0

2024

2023

0

2025\*

\*\*The 15 advanced therapies with OD and MA would be included in the total of 149 OMPs with MA, as they are advanced therapies with a brand name. Glossary: **OD** (orphan designation) OMPs (orphan medical products)
ATMPs (Advanced Therapy Medicinal Products) MA (Marketing Authorisation)

0

MΑ

2020

NC (National Code)
NHS (National Health System)

0

\*Cumulative data up to April 30, 2025.

2019

2018